Renaissance Technologies
CUE icon

Renaissance Technologies’s Cue Biopharma CUE Stock Holding History

Renaissance Technologies’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$464K Buy
14,689
+7,561
+106% +$171K ﹤0.01% 2624
2026
Q1 		$49.2K Sell
7,128
-817
-10% -$7.62K ﹤0.01% 3109
2025
Q4 		$72.8K Buy
7,945
+376
+5% +$6.91K ﹤0.01% 3050
2025
Q3 		$163K Buy
7,569
+3,120
+70% +$73.2K ﹤0.01% 3174
2025
Q2 		$91.1K Buy
4,449
+3,217
+261% +$68.6K ﹤0.01% 3316
2025
Q1 		$33.7K Buy
+1,232
New +$45.8K ﹤0.01% 3327
2024
Q2 		– Sell
-9,134
Closed -$518K – 3565
2024
Q1 		$518K Buy
9,134
+6,227
+214% +$439K ﹤0.01% 2850
2023
Q4 		$230K Buy
2,907
+914
+46% +$65.3K ﹤0.01% 3084
2023
Q3 		$138K Sell
1,993
-3,174
-61% -$310K ﹤0.01% 3176
2023
Q2 		$566K Buy
5,167
+3,464
+203% +$407K ﹤0.01% 2808
2023
Q1 		$182K Sell
1,703
-3,020
-64% -$288K ﹤0.01% 3314
2022
Q4 		$404K Sell
4,723
-9,482
-67% -$867K ﹤0.01% 3069
2022
Q3 		$950K Sell
14,205
-5,118
-26% -$440K ﹤0.01% 2529
2022
Q2 		$1.44M Buy
19,323
+2,013
+12% +$235K ﹤0.01% 2441
2022
Q1 		$2.53M Buy
17,310
+13,823
+396% +$2.93M ﹤0.01% 2050
2021
Q4 		$1.18M Buy
+3,487
New +$1.35M ﹤0.01% 2518
2021
Q1 		– Sell
-2,277
Closed -$854K – 3374
2020
Q4 		$854K Sell
2,277
-1,840
-45% -$735K ﹤0.01% 2580
2020
Q3 		$1.86M Buy
4,117
+750
+22% +$432K ﹤0.01% 2180
2020
Q2 		$2.48M Buy
3,367
+687
+26% +$498K ﹤0.01% 2070
2020
Q1 		$1.14M Buy
2,680
+1,234
+85% +$598K ﹤0.01% 2363
2019
Q4 		$689K Buy
+1,446
New +$454K ﹤0.01% 2782

Other funds holding CUE

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM

Renaissance Technologies's CUE Position: Q2 2026 in Review

Renaissance Technologies increased its Cue Biopharma (CUE) stake by 106% in Q2 2026, buying an estimated $171K and bringing the position to 14,689 shares worth $464K. The position accounts for ﹤0.01% of the portfolio, ranked #2624.

Renaissance Technologies first reported a position in CUE in Q4 2019 and has held it in 21 quarters since. The position peaked at $2.53M in Q1 2022. 49 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Renaissance Technologies held 14,689 shares of Cue Biopharma worth $464K as of Q2 2026.
  • Renaissance Technologies bought 7,561 Cue Biopharma shares in Q2 2026, an estimated $171K.
  • Cue Biopharma made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2624 holding.
  • Renaissance Technologies first reported a position in Cue Biopharma in Q4 2019 and has held it in 21 quarters since.
  • Renaissance Technologies's Cue Biopharma position peaked at $2.53M in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.